CagriSema, a combination of cagrilintide and semaglutide, is a promising treatment for obesity, especially in patients with type 2 diabetes and cardiovascular disease. The new drug combines two active ingredients :cagrilintide(a lake enzyme analogue) and semaglutide(a GLP-1 receptor agonist), both of which play important roles in appetite regulation and glucose control. CagriSema Action mechanism Semaglutide is best known for its …